CSPC Innovation Pharmaceutical (300765.SZ) subsidiary receives US$15 million milestone payment under exclusive licensing agreement signed with Corbus.

date
17:04 19/11/2026
avatar
GMT Eight
CSPC Innovation Pharmaceutical (300765.SZ) announced that its controlled subsidiary, CSPC Group Juishi Biopharmaceutical Co., Ltd. ("Juishi Biopharmaceutical"), received a US$15 million milestone payment from Corbus Pharmaceuticals, Inc. ("Corbus") on November 18, 2026. Prior to this, Juishi Biopharmaceutical had cumulatively received an aggregate of US$17.5 million in upfront and milestone payments from Corbus under the exclusive licensing agreement (excluding this payment). This payment is expected to have a positive impact on the company's performance and financial condition.
CSPC Innovation Pharmaceutical (300765.SZ) announced that its controlled subsidiary CSPC PHARMA Jushi Biopharmaceutical Co., Ltd. ("Jushi Biopharmaceutical") received a US$15 million milestone payment from Corbus Pharmaceuticals, Inc. ("Corbus") on November 18, 2026. Prior to this, Jushi Biopharmaceutical had cumulatively received an upfront payment and milestone payments totaling US$17.5 million from Corbus under the exclusive licensing agreement (excluding this payment). This payment is expected to have a positive impact on the company's performance and financial condition.